Macrophages, lipid metabolism and gene expression in atherogenesis: a therapeutic target of the future?

References

• Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell145(3), 341–355 (2011).
   Google Scholar
• Mclaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog.Lipid Res. 50(4), 331–347 (2011).
   Google Scholar
• Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature473(7347), 317–325 (2011).
   Google Scholar
• Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat.Rev.Immunol.10(1), 36–46 (2010).
   Google Scholar
• Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 17(11), 1410–1422 (2011).
   Google Scholar
• Bobryshev YV. Monocyte recruitment and foam cell formation in atherosclerosis. Micron 37(3), 208–222 (2006).
   Google Scholar
• Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation116(16), 1832–1844 (2007).
   Google Scholar
• Saha P, Modarai B, Humphries Jetal. The monocyte/macrophage as a therapeutic target in atherosclerosis. Curr.Opin.Pharmacol. 9(2), 109–118 (2009).
   Google Scholar
• Goldstein J, Ho Y, Basu S, Brown M. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc.NatlAcad.Sci.USA76(1), 333–337 (1979).
   Google Scholar
• Aqel NM, Ball RY, Waldmann H, Mitchinson MJ. Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis53(3), 265–271 (1984).
   Google Scholar
• Klurfeld DM. Identification of foam cells in human atherosclerotic lesions as macrophages using monoclonal antibodies. Arch.Pathol. Lab.Med.109(5), 445–449 (1985).
   Google Scholar
• Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc.NatlAcad.Sci.USA 92(18), 8264–8268 (1995).
   Google Scholar
• Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat.Immunol. 12(3), 204–212 (2011).
   Google Scholar
• Shimada K. Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circ.J.73(6), 994–1001 (2009).
   Google Scholar
• Gleissner CA, Shaked I, Little KM, Ley K. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J.Immunol.184(9), 4810–4818 (2010).
   Google Scholar
• Hirose K, Iwabuchi K, Shimada Ketal. Different responses to oxidized low-density lipoproteins in human polarized macrophages. LipidsHealthDis.10, 1 (2011).
   Google Scholar
• Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat. Rev.Cardiol.7(2), 77–86 (2010).
   Google Scholar
• Ikonen E. Mechanisms for cellular cholesterol transport: defects and human disease. Physiol. Rev.86(4), 1237–1261 (2006).
   Google Scholar
• van der Velde AE. Reverse cholesterol transport: from classical view to new insights. WorldJ.Gastroenterol. 16(47), 5908–5915 (2010).
   Google Scholar
• Plüddemann A, Neyen C, Gordon S. Macrophage scavenger receptors and host-derived ligands. Methods43(3), 207–217 (2007).
   Google Scholar
• Moore K, Freeman M. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler.Thromb.Vasc.Biol.26(8), 1702–1711 (2006).
   Google Scholar
• Nozaki S, Kashiwagi H, Yamashita Setal. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J.Clin.Invest.96(4), 1859–1865 (1995).
   Google Scholar
• Sugano R, Yamamura T, Harada-Shiba M, Miyake Y, Yamamoto A. Uptake of oxidized low-density lipoprotein in a THP-1 cell line lacking scavenger receptor A. Atherosclerosis 158(2), 351–357 (2001).
   Google Scholar
• Mitra S, Goyal T, Mehta JL. Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc.Drugs Ther. 25(5), 419–429 (2011).
   Google Scholar
• Zhang L, Liu HJ, Li TJetal. Lentiviral vector-mediated siRNA knockdown of SR-PSOX inhibits foam cell formation invitro. ActaPharmacol.Sin.29(7), 847–852 (2008).
   Google Scholar
• Smith EB, Ashall C. Low-density lipoprotein concentration in interstitial fluid from human atherosclerotic lesions. Relation to theories of endothelial damage and lipoprotein binding. Biochim.Biophys.Acta754(3), 249–257 (1983).
   Google Scholar
• Kerr M, Teasdale R. Defining macropinocytosis. Traffic10(4), 364–371 (2009).
   Google Scholar
• Mclaren JE, Michael DR, Guschina IA, Harwood JL, Ramji DP. Eicosapentaenoic acid and docosahexaenoic acid regulate modified LDL uptake and macropinocytosis in human macrophages. Lipids 46(11), 1053–1061 (2011).
   Google Scholar
• Anzinger JJ, Chang J, Xu Qetal. Native low-density lipoprotein uptake by macrophage colony-stimulating factor-differentiated human macrophages is mediated by macropinocytosis and micropinocytosis. Arterioscler.Thromb.Vasc.Biol.30(10), 2022–2031 (2010). Review article outlining the recent advances in experimental and clinical atherosclerotic research and the future prospects of cardiovascular disease therapies. Describes how macropinocytosis, a receptor-independent mechanism, can facilitate the uptake of LDL by macrophages and contribute to foam cell formation.
   Google Scholar
• Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler.Thromb.Vasc.Biol.30(2), 139–143 (2010).
   Google Scholar
• Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell.Metab.7(5), 365–375 (2008).
   Google Scholar
• Bodzioch M, Orso E, Klucken Jetal. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat.Genet.22(4), 347–351 (1999).
   Google Scholar
• Mukhamedova N, D’Souza W, Low H, Kesani R, Chimini G, Sviridov D. Global functional knockdown of ATP binding cassette transporter A1 stimulates development of atherosclerosis in apoE K/O mice. Biochem.Biophys.Res.Commun. 412(3), 446–449 (2011).
   Google Scholar
• Sankaranarayanan S, Oram JF, Asztalos BF etal. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. J.LipidRes.50(2), 275–284 (2009).
   Google Scholar
• Greenow K, Pearce NJ, Ramji DP. The key role of apolipoprotein E in atherosclerosis. J.Mol.Med.(Berl.)83(5), 329–342 (2005).
   Google Scholar
• Lucic D, Huang ZH, Gu de S, Altenburg MK, Maeda N, Mazzone T. Regulation of macrophage ApoE secretion and sterol efflux by the LDL receptor. J.LipidRes.48(2), 366–372 (2007).
   Google Scholar
• Lin CY, Lucas M, Mazzone T. Endogenous ApoE expression modulates HDL3 binding to macrophages. J.LipidRes.39(2), 293–301 (1998).
   Google Scholar
• Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 267(5200), 1034–1037 (1995).
   Google Scholar
• Fazio S, Babaev VR, Murray ABetal. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc.NatlAcad.Sci.USA94(9), 4647–4652 (1997).
   Google Scholar
• Ji Y, Jian B, Wang Netal. Scavenger receptor BI promotes high density lipoproteinmediated cellular cholesterol efflux. J.Biol. Chem.272(34), 20982–20985 (1997).
   Google Scholar
• de la Llera-Moya M, Rothblat GH, Connelly MAetal. Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface. J.Lipid Res.40(3), 575–580 (1999).
   Google Scholar
• Zhang W, Yancey PG, Su YRetal. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation108(18), 2258–2263 (2003).
   Google Scholar
• Covey SD, Krieger M, Wang W, Penman M, Trigatti BL. Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Arterioscler.Thromb.Vasc.Biol. 23(9), 1589–1594 (2003).
   Google Scholar
• Hoekstra M, Van Berkel TJ, Van Eck M. Scavenger receptor BI: a multi-purpose player in cholesterol and steroid metabolism. World J.Gastroenterol.16(47), 5916–5924 (2010).
   Google Scholar
• Chinetti-Gbaguidi G, Staels B. Lipid ligand-activated transcription factors regulating lipid storage and release in human macrophages. Biochim.Biophys.Acta1791(6), 486–493 (2009).
   Google Scholar
• Sekiya M, Osuga J, Igarashi M, Okazaki H, Ishibashi S. The role of neutral cholesterol ester hydrolysis in macrophage foam cells. J.Atheroscler.Thromb.18(5), 359–364 (2011).
   Google Scholar
• McLaren J, Calder C, McSharry Betal. The TNF-like protein 1A-death receptor 3 pathway promotes macrophage foam cell formation invitro. J.Immunol.184(10), 5827–5834 (2010).
   Google Scholar
• McLaren JE, Michael DR, Salter RCetal. IL-33 reduces macrophage foam cell formation. J.Immunol.185(2), 1222–1229 (2010).
   Google Scholar
• Klingenberg R, Hansson GK. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur.HeartJ.30(23), 2838–2844 (2009).
   Google Scholar
• Koga M, Kai H, Yasukawa Hetal. Inhibition of progression and stabilization of plaques by postnatal interferon-gamma function blocking in ApoE-knockout mice. Circ.Res. 101(4), 348–356 (2007).
   Google Scholar
• Abbate A, Salloum FN, Vecile Eetal. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation117(20), 2670–2683 (2008).
   Google Scholar
• Olofsson PS, Sheikine Y, Jatta Ketal. A functional interleukin-1 receptor antagonist polymorphism influences atherosclerosis development. The interleukin-1beta:interleukin-1 receptor antagonist balance in atherosclerosis. Circ.J.73(8), 1531–1536 (2009).
   Google Scholar
• Atzeni F, Turiel M, Caporali Retal. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun.Rev. 9(12), 835–839 (2010).
   Google Scholar
• Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. Curr. Opin.Rheumatol.23(3), 245–251 (2011).
   Google Scholar
• Chen S, Shimada K, Zhang W, Huang G, Crother TR, Arditi M. IL-17A is proatherogenic in high-fat diet-induced and Chlamydiapneumoniae infection-accelerated atherosclerosis in mice. J.Immunol.185(9), 5619–5627 (2010).
   Google Scholar
• Dretzke J, Edlin R, Round Jetal. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technol.Assess.15(6), 1–244 (2011).
   Google Scholar
• Kerekes G, Soltész P, Dér Hetal. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann.NYAcad.Sci.1173, 814–821 (2009).
   Google Scholar
• Rigamonti E, Chinetti-Gbaguidi G, Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler.Thromb.Vasc. Biol.28(6), 1050–1059 (2008).
   Google Scholar
• Szanto A, Roszer T. Nuclear receptors in macrophages: a link between metabolism and inflammation. FEBSLett.582(1), 106–116 (2008).
   Google Scholar
• Bouhlel MA, Staels B, Chinetti-Gbaguidi G. Peroxisome proliferator-activated receptors – from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease. J.Intern.Med.263(1), 28–42 (2008).
   Google Scholar
• Calkin AC, Tontonoz P. Liver X receptor signaling pathways and atherosclerosis. Arterioscler.Thromb.Vasc.Biol.30(8), 1513–1518 (2010).
   Google Scholar
• Sivagnanam G. Rosiglitazone and macular edema. CMAJ175(3), 276 (2006).
   Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N.Engl.J.Med. 356(24), 2457–2471 (2007).
   Google Scholar
• Im SS, Osborne TF. Liver X receptors in atherosclerosis and inflammation. Circ.Res. 108(8), 996–1001 (2011).
   Google Scholar
• Li N, Salter RC, Ramji DP. Molecular mechanisms underlying the inhibition of IFN-gamma-induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs. J.Cell.Biochem. 112(2), 675–683 (2011).
   Google Scholar
• Lobatto ME, Fuster V, Fayad ZA, Mulder WJ. Perspectives and opportunities for Important study showing the anti-foam cell properties of IL-33 in human macrophages, therefore highlighting it as a promising future therapeutic target. Review describing how nanoparticles may be used to deliver drugs directly and specifically to target cells during atherosclerotic therapies. nanomedicine in the management of atherosclerosis. Nat.Rev.DrugDiscov. 10(11), 835–852 (2011).
   Google Scholar
• Sadeghi MM, Glover DK, Lanza GM, Fayad ZA, Johnson LL. Imaging atherosclerosis and vulnerable plaque. J.Nucl.Med. 51(Suppl. 1), S51–S65 (2010).
   Google Scholar
• Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat.Rev.DrugDiscov. 10(5), 365–376 (2011).
   Google Scholar
• Bench TJ, Jeremias A, Brown DL. Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease. Pharmacol.Res. 64(6), 561–566 (2011).
   Google Scholar
• Corson MA. Darapladib: an emerging therapy for atherosclerosis. Ther.Adv. Cardiovasc.Dis.4(4), 241–248 (2010).
   Google Scholar
• White H, Held C, Stewart Retal. Study design and rationale for the clinical outcomes of the STABILITY Trial (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) comparing darapladib versus placebo in patients with coronary heart disease. Am.HeartJ.160(4), 655–661 (2010).
   Google Scholar
• Croons V, Martinet W, de Meyer GR. Selective removal of macrophages in atherosclerotic plaques as a pharmacological approach for plaque stabilization: benefits versus potential complications. Curr.Vasc. Pharmacol.8(4), 495–508 (2010).
   Google Scholar
• Evans M, Roberts A, Davies S, Rees A. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Drugs64(11), 1181–1196 (2004).
   Google Scholar
• Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat.Rev.DrugDiscov.4(12), 977–987 (2005).
   Google Scholar
• Hofnagel O, Luechtenborg B, Weissen-Plenz G, Robenek H. Statins and foam cell formation: impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors. Biochim.Biophys.Acta1771(9), 1117–1124 (2007).
   Google Scholar
• Mizuno Y, Jacob RF, Mason RP. Inflammation and the development of atherosclerosis. J.Atheroscler.Thromb.18(5), 351–358 (2011).
   Google Scholar
• Nachtigal P, Pospisilova N, Jamborova G etal. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. LifeSci. 82(13–14), 708–717 (2008).
   Google Scholar
• Quist-Paulsen P. Statins and inflammation: an update. Curr.Opin.Cardiol.25(4), 399–405 (2010).
   Google Scholar
• Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ.J.74(2), 213–220 (2010).
   Google Scholar
• Taylor F, Ward K, Moore THetal. Statins for the primary prevention of cardiovascular disease. CochraneDatabaseSyst.Rev. 1, CD004816 (2011).
   Google Scholar
• Getz GS, Wool GD, Reardon CA. HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders. Curr.Pharm.Des. 16(28), 3173–3184 (2010).
   Google Scholar
• Haas MJ, Mooradian AD. Therapeutic interventions to enhance apolipoprotein A-Imediated cardioprotection. Drugs70(7), 805–821 (2010).
   Google Scholar
• Tardif JC, Gregoire J, L’allier PLetal. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA297(15), 1675–1682 (2007).
   Google Scholar
• Meyer P, Nigam A, Marcil M, Tardif JC. The therapeutic potential of high-density lipoprotein mimetic agents in coronary artery disease. Curr.Atheroscler.Rep.11(5), 329–333 (2009).
   Google Scholar
• Bloedon LT, Dunbar R, Duffy Detal. Safety, pharmacokinetics, and pharmacodynamics of oral ApoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J.LipidRes. 49(6), 1344–1352 (2008). Interesting study providing evidence that single doses of the ApoA-I mimetic, D-4F, improves the anti-inflammatory actions of HDL in high-cardiovascular-risk patients, thus providing a rationale for further multiple-dose studies in humans.
   Google Scholar
• Martin K, O’Sullivan JF, Caplice NM. New therapeutic potential of microRNA treatment to target vulnerable atherosclerotic lesions and plaque rupture. Curr.Opin.Cardiol. 26(6), 569–575 (2011).
   Google Scholar
• Haver VG, Slart RH, Zeebregts CJ, Peppelenbosch MP, Tio RA. Rupture of vulnerable atherosclerotic plaques: microRNAs conducting the orchestra? Trends Cardiovasc.Med.20(2), 65–71 (2010).
   Google Scholar
• Huang RS, Hu GQ, Lin B, Lin ZY, Sun CC. MicroRNA-155 silencing enhances inflammatory response and lipid uptake in oxidized low-density lipoprotein-stimulated human THP-1 macrophages. J.Investig.Med. 58(8), 961–967 (2010).
   Google Scholar
• Rayner KJ, Esau CC, Hussain FNetal. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature478(7369), 404–407 (2011). Exciting new evidence showing that the inhibition of miR-33a/b, using modified antisense miRNA oligonucleotides, can raise HDL levels in a model that is highly relevant to humans.
   Google Scholar
• Vickers KC, Remaley AT. MicroRNAs in atherosclerosis and lipoprotein metabolism. Curr.Opin.Endocrinol.DiabetesObes.17(2), 150–155 (2010).
   Google Scholar